|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lei S, Zheng R, Zhang S, Wang S, Chen R,
Sun K, Zeng H, Zhou J and Wei W: Global patterns of breast cancer
incidence and mortality: A population-based cancer registry data
analysis from 2000 to 2020. Cancer Commun (Lond). 41:1183–1194.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gradishar WJ, Moran MS, Abraham J, Aft R,
Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, et
al: Breast cancer, version 3.2022, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 20:691–722.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Partridge AH, Burstein HJ and Winer EP:
Side effects of chemotherapy and combined chemohormonal therapy in
women with early-stage breast cancer. J Natl Cancer Inst Monogr.
(30):135–142. 2001.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Langeh U, Kumar V, Ahuja P, Singh C and
Singh A: An update on breast cancer chemotherapy-associated
toxicity and their management approaches. Health Sci Re.
9(100119)2023.
|
|
6
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J
Med. 365:1273–1283. 2011.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Darby SC, Ewertz M, McGale P, Bennet AM,
Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante
B, et al: Risk of ischemic heart disease in women after
radiotherapy for breast cancer. N Engl J Med. 368:987–998.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Adams S, Gatti-Mays ME, Kalinsky K, Korde
LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E,
Perlmutter J, et al: Current landscape of immunotherapy in breast
cancer: A review. JAMA Oncol. 5:1205–1214. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Verheijden RJ, van Eijs MJM, May AM, van
Wijk F and Suijkerbuijk KPM: Immunosuppression for immune-related
adverse events during checkpoint inhibition: An intricate balance.
NPJ Precis Oncol. 7(41)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Martins F, Sofiya L, Sykiotis GP, Lamine
F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A,
Guex-Crosier Y, et al: Adverse effects of immune-checkpoint
inhibitors: epidemiology, management and surveillance. Nat Rev Clin
Oncol. 6:563–580. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Trimboli RM, Giorgi Rossi P, Battisti NML,
Cozzi A, Magni V, Zanardo M and Sardanelli F: Do we still need
breast cancer screening in the era of targeted therapies and
precision medicine? Insights Imaging. 11(105)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Elemam NM, Talaat IM, Assal RA and Youness
RA: Understanding the crosstalk between immune cells and the tumor
microenvironment in cancer and its implications for immunotherapy.
Front Med (Lausanne). 10(1202581)2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cha YJ and Koo JS: Role of
tumor-associated myeloid cells in breast cancer. Cells.
9(1785)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ortiz ML, Lu L, Ramachandran I and
Gabrilovich DI: Myeloid-derived suppressor cells in the development
of lung cancer. Cancer Immunol Res. 2:50–58. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Srivastava MK, Zhu L, Harris-White M, Kar
UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S
and Sharma S: Myeloid suppressor cell depletion augments antitumor
activity in lung cancer. PLoS One. 7(e40677)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yang Z, Guo J, Weng L, Tang W, Jin S and
Ma W: Myeloid-derived suppressor cells-new and exciting players in
lung cancer. J Hematol Oncol. 13(10)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Blaye C, Boyer T, Peyraud F, Domblides C
and Larmonier N: Beyond immunosuppression: The multifaceted
functions of tumor-promoting myeloid cells in breast cancers. Front
Immunol. 13(838040)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li L, Li M and Jia Q: Myeloid-derived
suppressor cells: Key immunosuppressive regulators and therapeutic
targets in cancer. Pathol Res Pract. 248(154711)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Parker KH, Beury DW and Ostrand-Rosenberg
S: Myeloid-derived suppressor cells: critical cells driving immune
suppression in the tumor microenvironment. Adv Cancer Res.
128:95–139. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bronte V, Brandau S, Chen SH, Colombo MP,
Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A,
Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived
suppressor cell nomenclature and characterization standards. Nat
Commun. 7(12150)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cassetta L, Baekkevold ES, Brandau S,
Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O,
et al: Deciphering myeloid-derived suppressor cells: isolation and
markers in humans, mice, and non-human primates. Cancer Immunol
Immunother. 68:687–697. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang PF, Song SY, Wang TJ, Ji WJ, Li SW,
Liu N and Yan CX: Prognostic role of pretreatment circulating MDSCs
in patients with solid malignancies: A meta-analysis of 40 studies.
Oncoimmunology. 7(e1494113)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Condamine T, Mastio J and Gabrilovich DI:
Transcriptional regulation of myeloid-derived suppressor cells. J
Leukoc Biol. 98:913–922. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Alshetaiwi H, Pervolarakis N, McIntyre LL,
Ma D, Nguyen Q, Rath JA, Nee K, Hernandez G, Evans K, Torosian L,
et al: Defining the emergence of myeloid-derived suppressor cells
in breast cancer using single-cell transcriptomics. Sci Immunol.
5(eaay6017)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Millrud CR, Bergenfelz C and Leandersson
K: On the origin of myeloid-derived suppressor cells. Oncotarget.
8:3649–3665. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sun HW, Wu WC, Chen HT, Xu YT, Yang YY,
Chen J, Yu XJ, Wang Z, Shuang ZY and Zheng L: Glutamine deprivation
promotes the generation and mobilization of MDSCs by enhancing
expression of G-CSF and GM-CSF. Front Immunol.
11(616367)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rong Y, Yuan CH, Qu Z, Zhou H, Guan Q,
Yang N, Leng XH, Bu L, Wu K and Wang F: Doxorubicin-resistant
cancer cells activate myeloid-derived suppressor cells by releasing
PGE2. Sci Rep. 6(23824)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ching MM, Reader J and Fulton AM:
Eicosanoids in cancer: prostaglandin E2 receptor 4 in cancer
therapeutics and immunotherapy. Front Pharmacol.
11(530199)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Pradhan AK, Maji S, Bhoopathi P, Talukdar
S, Mannangatti P, Guo C, Wang XY, Cartagena LC, Idowu M, Landry JW,
et al: Pharmacological inhibition of MDA-9/Syntenin blocks breast
cancer metastasis through suppression of IL-1β. Proc Natl Acad Sci
USA. 118(e2103180118)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jiang M, Chen J, Zhang W, Zhang R, Ye Y,
Liu P, Yu W, Wei F, Ren X and Yu J: Interleukin-6 trans-signaling
pathway promotes immunosuppressive myeloid-derived suppressor cells
via suppression of suppressor of cytokine signaling 3 in breast
cancer. Front Immunol. 8(1840)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhao N, Zhu W, Wang J, Liu W, Kang L, Yu R
and Liu B: Group 2 innate lymphoid cells promote TNBC lung
metastasis via the IL-13-MDSC axis in a murine tumor model. Int
Immunopharmacol. 99(107924)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Popović M, Dedić Plavetić N, Vrbanec D,
Marušić Z, Mijatović D and Kulić A: Interleukin 17 in early
invasive breast cancer. Front Oncol. 13(1171254)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Gao W, Wen H, Liang L, Dong X, Du R, Zhou
W, Zhang X, Zhang C, Xiang R and Li N: IL20RA signaling enhances
stemness and promotes the formation of an immunosuppressive
microenvironment in breast cancer. Theranostics. 11:2564–2580.
2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong
J, Zheng M, Song Y, Chen L, He J, et al: Interleukin 33 in tumor
microenvironment is crucial for the accumulation and function of
myeloid-derived suppressor cells. Oncoimmunology.
5(e1063772)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kajihara N, Kobayashi T, Otsuka R,
Nio-Kobayashi J, Oshino T, Takahashi M, Imanishi S, Hashimoto A,
Wada H and Seino KI: Tumor-derived interleukin-34 creates an
immunosuppressive and chemoresistant tumor microenvironment by
modulating myeloid-derived suppressor cells in triple-negative
breast cancer. Cancer Immunol Immunother. 72:851–864.
2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Simpson KD, Templeton DJ and Cross JV:
Macrophage migration inhibitory factor promotes tumor growth and
metastasis by inducing myeloid-derived suppressor cells in the
tumor microenvironment. J Immunol. 189:5533–5540. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Liu QW, Chen Y, Li JY, Xiao L, Zhang WJ,
Zhao JL, Gu HC, Wu HY, Zuo GS, Deng KY and Xin HB: Bone marrow
cells are differentiated into MDSCs by BCC-Ex through
down-regulating the expression of CXCR4 and activating the STAT3
signalling pathway. J Cell Mol Med. 25:5497–5510. 2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mundy-Bosse BL, Thornton LM, Yang HC,
Andersen BL and Carson WE: Psychological stress is associated with
altered levels of myeloid-derived suppressor cells in breast cancer
patients. Cell Immunol. 270:80–87. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
He K, Liu X, Hoffman RD, Shi RZ, Lv GY and
Gao JL: G-CSF/GM-CSF-induced hematopoietic dysregulation in the
progression of solid tumors. FEBS Open Bio. 12:1268–1285.
2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Smith KG and Clatworthy MR: FcγRIIB in
autoimmunity and infection: Evolutionary and therapeutic
implications. Nat Rev Immunol. 10:328–343. 2010.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wu L, Xu Y, Zhao H, Zhou Y, Chen Y, Yang
S, Lei J, Zhang J, Wang J, Wu Y and Li Y: FcγRIIB potentiates
differentiation of myeloid-derived suppressor cells to mediate
tumor immunoescape. Theranostics. 12:842–858. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hillmer EJ, Zhang H, Li HS and Watowich
SS: STAT3 signaling in immunity. Cytokine Growth Factor Rev.
31:1–15. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liao WC, Yen HR, Chen CH, Chu YH, Song YC,
Tseng TJ and Liu CH: CHPF promotes malignancy of breast cancer
cells by modifying syndecan-4 and the tumor microenvironment. Am J
Cancer Res. 11:812–826. 2021.PubMed/NCBI
|
|
44
|
Liu C, Qiang J, Deng Q, Xia J, Deng L,
Zhou L, Wang D, He X, Liu Y, Zhao B, et al: ALDH1A1 activity in
tumor-initiating cells remodels myeloid-derived suppressor cells to
promote breast cancer progression. Cancer Res. 81:5919–5934.
2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Jiang M, Zhang W, Zhang R, Liu P, Ye Y, Yu
W, Guo X and Yu J: Cancer exosome-derived miR-9 and miR-181a
promote the development of early-stage MDSCs via interfering with
SOCS3 and PIAS3 respectively in breast cancer. Oncogene.
39:4681–4694. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang W, Jiang M, Chen J, Zhang R, Ye Y,
Liu P, Yu W and Yu J: SOCS3 suppression promoted the recruitment of
CD11b+ Gr-1-F4/80-MHCII-early-stage myeloid-derived suppressor
cells and accelerated interleukin-6-related tumor invasion via
affecting myeloid differentiation in breast cancer. Front Immunol.
9(1699)2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Welte T, Kim IS, Tian L, Gao X, Wang H, Li
J, Holdman XB, Herschkowitz JI, Pond A, Xie G, et al: Oncogenic
mTOR signalling recruits myeloid-derived suppressor cells to
promote tumour initiation. Nat Cell Biol. 18:632–644.
2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ozga AJ, Chow MT and Luster AD: Chemokines
and the immune response to cancer. Immunity. 54:859–874.
2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Huang YC, Hou MF, Tsai YM, Pan YC, Tsai
PH, Lin YS, Chang CY, Tsai EM and Hsu YL: Involvement of ACACA
(acetyl-CoA carboxylase α) in the lung pre-metastatic niche
formation in breast cancer by senescence phenotypic conversion in
fibroblasts. Cell Oncol (Dordr). 46:643–660. 2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Gu P, Sun M, Li L, Yang Y, Jiang Z, Ge Y,
Wang W, Mu W and Wang H: Breast tumor-derived exosomal
microRNA-200b-3p promotes specific organ metastasis through
regulating CCL2 expression in lung epithelial cells. Front Cell Dev
Biol. 9(657158)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Tanaka T, Kajiwara T, Torigoe T, Okamoto
Y, Sato N and Tamura Y: Cancer-associated oxidoreductase ERO1-α
drives the production of tumor-promoting myeloid-derived suppressor
cells via oxidative protein folding. J Immunol. 194:2004–2010.
2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F,
Wang X, Wang J, Yu H, Cao X and Wang Q: MicroRNA-494 is required
for the accumulation and functions of tumor-expanded
myeloid-derived suppressor cells via targeting of PTEN. J Immunol.
188:5500–5510. 2012.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng
W, Zheng Q, Chen C and Sun S: Breast cancer heterogeneity and its
implication in personalized precision therapy. Exp Hematol Oncol.
12(3)2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Vrakas CN, O'Sullivan RM, Evans SE, Ingram
DA, Jones CB, Phuong T and Kurt RA: The Measure of DAMPs and a role
for S100A8 in recruiting suppressor cells in breast cancer lung
metastasis. Immunol Invest. 44:174–188. 2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chen JY, Lai YS, Chu PY, Chan SH, Wang LH
and Hung WC: Cancer-derived VEGF-C increases chemokine production
in lymphatic endothelial cells to promote CXCR2-dependent cancer
invasion and MDSC recruitment. Cancers (Basel).
11(1120)2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Roberts LM, Perez MJ, Balogh KN,
Mingledorff G, Cross JV and Munson JM: Myeloid derived suppressor
cells migrate in response to flow and lymphatic endothelial cell
interaction in the breast tumor microenvironment. Cancers (Basel).
14(3008)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng
SY, Chen C, Chen G, Li Y and Feng H: KAT6A acetylation of SMAD3
regulates myeloid-derived suppressor cell recruitment, metastasis,
and immunotherapy in triple-negative breast cancer. Adv Sci
(Weinh). 8(e2100014)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Vadrevu SK, Chintala NK, Sharma SK, Sharma
P, Cleveland C, Riediger L, Manne S, Fairlie DP, Gorczyca W,
Almanza O, et al: Complement c5a receptor facilitates cancer
metastasis by altering T-cell responses in the metastatic niche.
Cancer Res. 74:3454–3465. 2014.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Cheng R, Billet S, Liu C, Haldar S,
Choudhury D, Tripathi M, Hav M, Merchant A, Hu T, Huang H, et al:
Periodontal inflammation recruits distant metastatic breast cancer
cells by increasing myeloid-derived suppressor cells. Oncogene.
39:1543–1556. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Tcyganov E, Mastio J, Chen E and
Gabrilovich DI: Plasticity of myeloid-derived suppressor cells in
cancer. Curr Opin Immunol. 51:76–82. 2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mehta AK, Kadel S, Townsend MG, Oliwa M
and Guerriero JL: Macrophage biology and mechanisms of immune
suppression in breast cancer. Front Immunol.
12(643771)2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Ostrand-Rosenberg S and Fenselau C:
Myeloid-derived suppressor cells: immune-suppressive cells that
impair antitumor immunity and are sculpted by their environment. J
Immunol. 200:422–431. 2018.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Cayrol C and Girard JP: Interleukin-33
(IL-33): A critical review of its biology and the mechanisms
involved in its release as a potent extracellular cytokine.
Cytokine. 156(155891)2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Mattiola I and Diefenbach A: Enabling
anti-tumor immunity by unleashing ILC2. Cell Res. 30:461–462.
2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Halvorsen EC, Franks SE, Wadsworth BJ,
Harbourne BT, Cederberg RA, Steer CA, Martinez-Gonzalez I, Calder
J, Lockwood WW and Bennewith KL: IL-33 increases ST2+ Tregs and
promotes metastatic tumour growth in the lungs in an
amphiregulin-dependent manner. Oncoimmunology.
8(e1527497)2018.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Gurram RK and Zhu J: Orchestration between
ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol
Immunol. 16:225–235. 2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Choi MR, Sosman JA and Zhang B: The janus
face of IL-33 signaling in tumor development and immune escape.
Cancers (Basel). 13(3281)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Huang X, Cao J and Zu X: Tumor-associated
macrophages: An important player in breast cancer progression.
Thorac Cancer. 13:269–276. 2022.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR
and Yang SM: Macrophages in tumor microenvironments and the
progression of tumors. Clin Dev Immunol.
2012(948098)2012.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Boutilier AJ and Elsawa SF: Macrophage
polarization states in the tumor microenvironment. Int J Mol Sci.
22(6995)2021.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Wang S, Wang J, Chen Z, Luo J, Guo W, Sun
L and Lin L: Targeting M2-like tumor-associated macrophages is a
potential therapeutic approach to overcome antitumor drug
resistance. NPJ Precis Oncol. 8(31)2024.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H,
Xiao GG, Rao L and Duo Y: Macrophages in immunoregulation and
therapeutics. Signal Transduct Target Ther. 8(207)2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Biswas S, Mandal G, Roy Chowdhury S,
Purohit S, Payne KK, Anadon C, Gupta A, Swanson P, Yu X,
Conejo-Garcia JR and Bhattacharyya A: Exosomes produced by
mesenchymal stem cells drive differentiation of myeloid cells into
immunosuppressive M2-polarized macrophages in breast cancer. J
Immunol. 203:3447–3460. 2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Payne KK, Zoon CK, Wan W, Marlar K, Keim
RC, Kenari MN, Kazim AL, Bear HD and Manjili MH: Peripheral blood
mononuclear cells of patients with breast cancer can be
reprogrammed to enhance anti-HER-2/neu reactivity and overcome
myeloid-derived suppressor cells. Breast Cancer Res Treat.
142:45–57. 2013.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Pansy K, Uhl B, Krstic J, Szmyra M,
Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K,
et al: Immune regulatory processes of the tumor microenvironment
under malignant conditions. Int J Mol Sci. 22(13311)2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Li F, Zhao Y, Wei L, Li S and Liu J:
Tumor-infiltrating Treg, MDSC, and IDO expression associated with
outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol
Ther. 19:695–705. 2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Srivastava MK, Sinha P, Clements VK,
Rodriguez P and Ostrand-Rosenberg S: Myeloid-derived suppressor
cells inhibit T-cell activation by depleting cystine and cysteine.
Cancer Res. 70:68–77. 2010.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Lu T, Ramakrishnan R, Altiok S, Youn JI,
Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB and Gabrilovich D:
Tumor-infiltrating myeloid cells induce tumor cell resistance to
cytotoxic T cells in mice. J Clin Invest. 121:4015–4029.
2011.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Stiff A, Trikha P, Mundy-Bosse B,
McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S and
Abood D: , et al: Nitric oxide production by myeloid-derived
suppressor cells plays a role in impairing Fc receptor-mediated
natural killer cell function. Clin Cancer Res. 24:1891–1904.
2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Sceneay J, Griessinger CM, Hoffmann SHL,
Wen SW, Wong CSF, Krumeich S, Kneilling M, Pichler BJ and Möller A:
Tracking the fate of adoptively transferred myeloid-derived
suppressor cells in the primary breast tumor microenvironment. PLoS
One. 13(e0196040)2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Hanson EM, Clements VK, Sinha P, Ilkovitch
D and Ostrand-Rosenberg S: Myeloid-derived suppressor cells
down-regulate L-selectin expression on CD4+ and CD8+ T cells. J
Immunol. 183:937–944. 2009.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Sinha P, Chornoguz O, Clements VK,
Artemenko KA, Zubarev RA and Ostrand-Rosenberg S: Myeloid-derived
suppressor cells express the death receptor Fas and apoptose in
response to T cell-expressed FasL. Blood. 117:5381–5390.
2011.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Lelis FJ, Jaufmann J, Singh A, Fromm K,
Teschner AC, Pöschel S, Schäfer I, Beer-Hammer S, Rieber N and
Hartl D: Myeloid-derived suppressor cells modulate B-cell
responses. Immunol Lett. 188:108–115. 2017.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Shen M, Wang J, Yu W, Zhang C, Liu M, Wang
K, Yang L, Wei F, Wang SE, Sun Q and Ren X: A novel MDSC-induced
PD-1- PD-L1+ B-cell subset in breast tumor microenvironment
possesses immuno-suppressive properties. Oncoimmunology.
7(e1413520)2018.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Nam S, Lee A, Lim J and Lim JS: Analysis
of the expression and regulation of PD-1 protein on the surface of
myeloid-derived suppressor cells (MDSCs). Biomol Ther (Seoul).
27:63–70. 2019.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Liu M, Wei F, Wang J, Yu W, Shen M, Liu T,
Zhang D, Wang Y, Ren X and Sun Q: Myeloid-derived suppressor cells
regulate the immunosuppressive functions of PD-1- PD-L1+ Bregs
through PD-L1/PI3K/AKT/NF-κB axis in breast cancer. Cell Death Dis.
12(465)2021.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Spallanzani RG, Dalotto-Moreno T, Raffo
Iraolagoitia XL, Ziblat A, Domaica CI, Avila DE, Rossi LE, Fuertes
MB, Battistone MA, Rabinovich GA, et al: Expansion of CD11b+ Ly6G+
Ly6C int cells driven by medroxyprogesterone acetate in mice
bearing breast tumors restrains NK cell effector functions. Cancer
Immunol Immunother. 62:1781–1795. 2013.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Sceneay J, Chow MT, Chen A, Halse HM, Wong
CS, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ and
Möller A: Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+
immune suppressor cells and compromises NK cell cytotoxicity in the
premetastatic niche. Cancer Res. 72:3906–3911. 2012.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Deng Z, Rong Y, Teng Y, Zhuang X,
Samykutty A, Mu J, Zhang L, Cao P, Yan J, Miller D and Zhang HG:
Exosomes miR-126a released from MDSC induced by DOX treatment
promotes lung metastasis. Oncogene. 36:639–651. 2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Ma X, Wang M, Yin T, Zhao Y and Wei X:
Myeloid-derived suppressor cells promote metastasis in breast
cancer after the stress of operative removal of the primary cancer.
Front Oncol. 9(855)2019.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Bergenfelz C, Roxå A, Mehmeti M,
Leandersson K and Larsson AM: Clinical relevance of systemic
monocytic-MDSCs in patients with metastatic breast cancer. Cancer
Immunol Immunother. 69:435–448. 2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Liu H, Wang Z, Zhou Y and Yang Y: MDSCs in
breast cancer: An important enabler of tumor progression and an
emerging therapeutic target. Front Immunol.
14(1199273)2023.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Veglia F, Perego M and Gabrilovich D:
Myeloid-derived suppressor cells coming of age. Nat Immunol.
19:108–119. 2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Gatti-Mays ME, Balko JM, Gameiro SR, Bear
HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky
K, et al: If we build it they will come: targeting the immune
response to breast cancer. NPJ Breast Cancer. 5(37)2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Kim K, Skora AD, Li Z, Liu Q, Tam AJ,
Blosser RL, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B
and Zhou S: Eradication of metastatic mouse cancers resistant to
immune checkpoint blockade by suppression of myeloid-derived cells.
Proc Natl Acad Sci USA. 111:11774–11779. 2014.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Le HK, Graham L, Cha E, Morales JK,
Manjili MH and Bear HD: Gemcitabine directly inhibits myeloid
derived suppressor cells in BALB/c mice bearing 4T1 mammary
carcinoma and augments expansion of T cells from tumor-bearing
mice. Int Immunopharmacol. 9:900–909. 2009.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Alizadeh D, Trad M, Hanke NT, Larmonier
CB, Janikashvili N, Bonnotte B, Katsanis E and Larmonier N:
Doxorubicin eliminates myeloid-derived suppressor cells and
enhances the efficacy of adoptive T-cell transfer in breast cancer.
Cancer Res. 74:104–118. 2014.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061.
2010.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Sharma P, Abramson V, O’Dea A, Nye L,
Mayer I, Crane G, Elia M, Yoder R, Staley J, Schwensen K, et al:
Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination
in patients with metastatic triple negative breast cancer (mTNBC).
J Clin Oncol. 39(10.1200/JCO.2021.39.15_suppl.1076)2021.
|
|
101
|
Davis RJ, Moore EC, Clavijo PE, Friedman
J, Cash H, Chen Z, Silvin C, Van Waes C and Allen C: Anti-PD-L1
efficacy can be enhanced by inhibition of myeloid-derived
suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer Res.
77:2607–2619. 2017.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G,
Liu A, Wang TC and Yang CS: Curcumin induces the differentiation of
myeloid-derived suppressor cells and inhibits their interaction
with cancer cells and related tumor growth. Cancer Prev Res
(Phila). 5:205–215. 2012.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Sánchez-León ML, Jiménez-Cortegana C,
Silva Romeiro S, Garnacho C, de la Cruz-Merino L, García-Domínguez
DJ, Hontecillas-Prieto L and Sánchez-Margalet V: Defining the
emergence of new immunotherapy approaches in breast cancer: Role of
myeloid-derived suppressor cells. Int J Mol Sci.
24(5208)2023.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Kusmartsev S, Cheng F, Yu B, Nefedova Y,
Sotomayor E, Lush R and Gabrilovich D: All-trans-retinoic acid
eliminates immature myeloid cells from tumor-bearing mice and
improves the effect of vaccination. Cancer Res. 63:4441–4449.
2003.PubMed/NCBI
|
|
105
|
Iclozan C, Antonia S, Chiappori A, Chen DT
and Gabrilovich D: Therapeutic regulation of myeloid-derived
suppressor cells and immune response to cancer vaccine in patients
with extensive stage small cell lung cancer. Cancer Immunol
Immunother. 62:909–918. 2013.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Forghani P, Khorramizadeh MR and Waller
EK: Silibinin inhibits accumulation of myeloid-derived suppressor
cells and tumor growth of murine breast cancer. Cancer Med.
3:215–224. 2014.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Sawant A, Deshane J, Jules J, Lee CM,
Harris BA, Feng X and Ponnazhagan S: Myeloid-derived suppressor
cells function as novel osteoclast progenitors enhancing bone loss
in breast cancer. Cancer Res. 73:672–682. 2013.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Kugler A, Stuhler G, Walden P, Zöller G,
Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker
V, et al: Regression of human metastatic renal cell carcinoma after
vaccination with tumor cell-dendritic cell hybrids. Nat Med.
6:332–336. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
109
|
Thakur A, Schalk D, Sarkar SH, Al-Khadimi
Z, Sarkar FH and Lum LG: A Th1 cytokine-enriched microenvironment
enhances tumor killing by activated T cells armed with bispecific
antibodies and inhibits the development of myeloid-derived
suppressor cells. Cancer Immunol Immunother. 61:497–509.
2012.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Kmieciak M, Basu D, Payne KK, Toor A,
Yacoub A, Wang XY, Smith L, Bear HD and Manjili MH: Activated NK T
cells and NK cells render T cells resistant to MDSC and result in
an effective adoptive cellular therapy against breast cancer in the
FVBN202 transgenic mouse. J Immunol. 187:708–717. 2011.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Chandra D, Jahangir A, Quispe-Tintaya W,
Einstein MH and Gravekamp C: Myeloid-derived suppressor cells have
a central role in attenuated Listeria monocytogenes-based
immunotherapy against metastatic breast cancer in young and old
mice. Br J Cancer. 108:2281–2290. 2013.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Chaves NL, Amorim DA, Lopes CAP,
Estrela-Lopis I, Böttner J, de Souza AR and Báo SN: Comparison of
the effect of rhodium citrate-associated iron oxide nanoparticles
on metastatic and non-metastatic breast cancer cells. Cancer Nano.
10:1–12. 2019.
|
|
113
|
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang
Y, Wu S, Deng Y, Zhang J and Shao A: Nanoparticle-based drug
delivery in cancer therapy and its role in overcoming drug
resistance. Front Mol Biosci. 7(193)2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Chaves NL, Estrela-Lopis I, Böttner J,
Lopes CA, Guido BC, de Sousa AR and Báo SN: Exploring cellular
uptake of iron oxide nanoparticles associated with rhodium citrate
in breast cancer cells. Int J Nanomedicine. 12:5511–5523.
2017.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Figueiro Longo JP and Muehlmann LA:
Nanomedicine beyond tumor passive targeting: What next?
Nanomedicine (Lond). 15:1819–1822. 2020.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Zhang N, Liu S, Shi S, Chen Y, Xu F, Wei X
and Xu Y: Solubilization and delivery of Ursolic-acid for
modulating tumor microenvironment and regulatory T cell activities
in cancer immunotherapy. J Control Release. 320:168–178.
2020.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Chen C, Li A, Sun P, Xu J, Du W, Zhang J,
Liu Y, Zhang R, Zhang S, Yang Z, et al: Efficiently restoring the
tumoricidal immunity against resistant malignancies via an immune
nanomodulator. J Control Release. 324:574–585. 2020.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Ali R, Shao H and Varamini P: Potential
Nanotechnology-Based Therapeutics to Prevent Cancer Progression
through TME Cell-Driven Populations. Pharmaceutics.
15(112)2022.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Lu Z, Liu H, Ma L, Ren K, He Z, Li M and
He Q: Micellar nanoparticles inhibit breast cancer and pulmonary
metastasis by modulating the recruitment and depletion of
myeloid-derived suppressor cells. Nanoscale. 14:17315–17330.
2022.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Debien V, De Caluwé A, Wang X,
Piccart-Gebhart M, Tuohy VK, Romano E and Buisseret L:
Immunotherapy in breast cancer: An overview of current strategies
and perspectives. NPJ Breast Cancer. 9(7)2023.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Teschendorff AE, Miremadi A, Pinder SE,
Ellis IO and Caldas C: An immune response gene expression module
identifies a good prognosis subtype in estrogen receptor negative
breast cancer. Genome Biol. 8(R157)2007.PubMed/NCBI View Article : Google Scholar
|
